Compare FLNT & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNT | VRCA |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.1M | 88.0M |
| IPO Year | 2009 | 2018 |
| Metric | FLNT | VRCA |
|---|---|---|
| Price | $3.03 | $4.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.50 | ★ $17.00 |
| AVG Volume (30 Days) | 32.3K | ★ 101.8K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,764,000.00 | $35,577,000.00 |
| Revenue This Year | $5.89 | N/A |
| Revenue Next Year | $12.62 | $94.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $1.70 | $3.28 |
| 52 Week High | $4.49 | $9.82 |
| Indicator | FLNT | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 30.66 | 43.32 |
| Support Level | $2.95 | $4.52 |
| Resistance Level | $3.05 | $5.94 |
| Average True Range (ATR) | 0.21 | 0.40 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 8.52 | 27.20 |
Fluent Inc is a commerce media solutions provider that connects brands with engaged consumers by leveraging diverse advertising inventory, robust first-party data, and proprietary machine learning. The company mainly delivers customer acquisition services through scalable digital marketing campaigns, linking advertisers with targeted audiences. It reaches consumers through its Commerce Media Solutions, which integrate targeted advertising into e-commerce and digital media transaction flows on partner websites and mobile applications, as well as through its owned and operated digital media properties. The company operates in the United States, which generates the majority of its revenue, along with international markets.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.